Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible

When tissue biopsy is not medically prudent or tissue is insufficient for molecular testing, alternative methods are needed. Because cell-free DNA (cfDNA) has been shown to provide a representative surrogate for tumor tissue, we sought to evaluate its utility in this clinical scenario. cfDNA was iso...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Taylor J., Goodman, Aaron M., Ellison, Christopher K., Holden, Kimberly A., Kato, Shumei, Kim, Lisa, Daniels, Gregory A., Fitzgerald, Kerry, McCarthy, Erin, Nakashe, Prachi, Mazloom, Amin R., Almasri, Eyad, McLennan, Graham, Grosu, Daniel S., Eisenberg, Marcia, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398131/
https://www.ncbi.nlm.nih.gov/pubmed/34465593
http://dx.doi.org/10.1158/1535-7163.MCT-20-1066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398131/
https://www.ncbi.nlm.nih.gov/pubmed/34465593
http://dx.doi.org/10.1158/1535-7163.MCT-20-1066

Ejemplares similares